Conduit Pharmaceuticals Inc. (CDT)
After hours:
| Previous Close | 0.1079 |
| Open | 0.1079 |
| Bid | 0.1008 x 100 |
| Ask | 0.1068 x 100 |
| Day's Range | 0.0971 - 0.1080 |
| 52 Week Range | 0.0790 - 7.8300 |
| Volume | |
| Avg. Volume | 22,139,950 |
| Market Cap | 10.696M |
| Beta (5Y Monthly) | 2.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2300 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders
Approval of composition of matter patent in key jurisdiction underscores the Company’s commitment to maximize future out-licensing valueNAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announced that the Japan Patent Office (JPO) has granted approval of a composition of matter patent application for the Company’s lead asset, AZD1656, a Glucokinase Activator targ
- GlobeNewswire
Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors
Conduit Pharmaceuticals strengthens its Board of Directors with the addition of Simon Fry, a seasoned investment banking executive with over 30 years of experience in asset management, capital markets, and strategy development. NAPLES, Fla. and CAMBRIDGE, United Kingdom, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a multi-asset, clinical stage, disease-agnostic life science company delivering an efficient model for compound developme
